Hansa reports Phase II data of IdeS in kidney transplant patients

Hansa Medical AB (SSE:HMED) reported interim data from 18 highly sensitized patients awaiting a kidney transplant with a positive crossmatch test prior

Read the full 221 word article

User Sign In